MA27730A1 - Combinaisons de paroxetine et de 4-(s)-(4-acetyl-piperazin-1-yl-)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-acide carboxylique[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxiete - Google Patents
Combinaisons de paroxetine et de 4-(s)-(4-acetyl-piperazin-1-yl-)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-acide carboxylique[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxieteInfo
- Publication number
- MA27730A1 MA27730A1 MA28561A MA28561A MA27730A1 MA 27730 A1 MA27730 A1 MA 27730A1 MA 28561 A MA28561 A MA 28561A MA 28561 A MA28561 A MA 28561A MA 27730 A1 MA27730 A1 MA 27730A1
- Authority
- MA
- Morocco
- Prior art keywords
- phenyl
- combinations
- methylamide
- paroxetine
- piperazin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Associations de paroxétine et de [1-(R)-(3,5-bis-trifluorométhylphényl)-éthyl]méthylamide d'acide 4-(S)-(4-acétyl-pipérazine-1-yl)-2-(R)-(4-fluoro-2-méthyl-pipéridine-1-carboxylique pour le traitement de la dépression et de l'anxiété La présente invention concerne des associations thérapeutiques comprenant de la paroxétine ou ses sels ou produits de solvatation physiologiquement acceptables et du [1-(R)-(3,5-bis-trifluorométhylphényl)-éthyl]-méthylamide d'acide 4-(S)-{4-acétyl-pipérazine-1-yl)-2-(R)-(4-fluoro-2-méthyl-phényl)-pipéridine-1-carboxylique ou de ses sels ou produits de solvatation pharmaceutiquement acceptables, des compositions pharmaceutiques contenant lesdites associations et leur utilisation dans le traitement de la dépression et/ou de l'anxiété.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0308968.7A GB0308968D0 (en) | 2003-04-17 | 2003-04-17 | Medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27730A1 true MA27730A1 (fr) | 2006-01-02 |
Family
ID=9956996
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28561A MA27730A1 (fr) | 2003-04-17 | 2005-10-19 | Combinaisons de paroxetine et de 4-(s)-(4-acetyl-piperazin-1-yl-)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-acide carboxylique[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxiete |
MA28562A MA27731A1 (fr) | 2003-04-17 | 2005-10-19 | Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28562A MA27731A1 (fr) | 2003-04-17 | 2005-10-19 | Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete |
Country Status (18)
Country | Link |
---|---|
US (4) | US20060287325A1 (fr) |
EP (4) | EP1615641A1 (fr) |
JP (4) | JP2006523650A (fr) |
KR (2) | KR20060003876A (fr) |
CN (2) | CN1809355A (fr) |
AU (2) | AU2004229179A1 (fr) |
BR (2) | BRPI0409379A (fr) |
CA (2) | CA2522313A1 (fr) |
CO (1) | CO5700753A2 (fr) |
GB (1) | GB0308968D0 (fr) |
IS (2) | IS8128A (fr) |
MA (2) | MA27730A1 (fr) |
MX (2) | MXPA05011064A (fr) |
NO (2) | NO20055367L (fr) |
PL (2) | PL377857A1 (fr) |
RU (2) | RU2005135647A (fr) |
WO (4) | WO2004091624A1 (fr) |
ZA (2) | ZA200508067B (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
GB0403149D0 (en) * | 2004-02-12 | 2004-03-17 | Glaxo Group Ltd | Medicament |
GB0409098D0 (en) * | 2004-04-23 | 2004-05-26 | Glaxo Group Ltd | Medicament |
GB0426942D0 (en) * | 2004-12-08 | 2005-01-12 | Glaxo Group Ltd | Medicament |
WO2007012968A2 (fr) * | 2005-07-29 | 2007-02-01 | Aurobindo Pharma Ltd | Forme dosifee stable d'un antidepresseur |
GB0621229D0 (en) * | 2006-10-20 | 2006-12-06 | Glaxo Group Ltd | Novel use |
WO2008090117A1 (fr) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Nouvelles compositions pharmaceutiques |
WO2012175434A1 (fr) * | 2011-06-20 | 2012-12-27 | Glaxo Group Limited | Formulations pharmaceutiques comprenant du vestipitant |
CN103446066B (zh) * | 2013-09-16 | 2014-12-24 | 南通丝乡丝绸有限公司 | 帕罗西汀冻干粉针及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111002A (en) * | 1993-09-22 | 1998-09-24 | Glaxo Group Ltd | History of piperidine, their preparation and the pharmaceutical preparations containing them |
US6117855A (en) * | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
US6162805A (en) * | 1997-04-24 | 2000-12-19 | Merck Sharp & Dohme Limited | Use of an NK-1 receptor antagonist and an SSRI for treating obesity |
GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
WO2001044200A2 (fr) * | 1999-12-17 | 2001-06-21 | Schering Corporation | Antagonistes selectifs de la neurokine |
US6436928B1 (en) * | 1999-12-17 | 2002-08-20 | Schering Corporation | Selective neurokinin antagonists |
GT200100147A (es) * | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
GB0025354D0 (en) * | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
GB0119797D0 (en) * | 2001-08-14 | 2001-10-03 | Glaxo Group Ltd | Chemical compounds |
CA2466465A1 (fr) * | 2001-11-13 | 2003-05-22 | Schering Corporation | Antagonistes de nk1 |
GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
-
2003
- 2003-04-17 GB GBGB0308968.7A patent/GB0308968D0/en not_active Ceased
-
2004
- 2004-04-16 PL PL377857A patent/PL377857A1/pl not_active Application Discontinuation
- 2004-04-16 AU AU2004229179A patent/AU2004229179A1/en not_active Abandoned
- 2004-04-16 JP JP2006505186A patent/JP2006523650A/ja active Pending
- 2004-04-16 PL PL377858A patent/PL377858A1/pl not_active Application Discontinuation
- 2004-04-16 BR BRPI0409379-8A patent/BRPI0409379A/pt not_active Application Discontinuation
- 2004-04-16 AU AU2004229181A patent/AU2004229181A1/en not_active Abandoned
- 2004-04-16 US US10/552,982 patent/US20060287325A1/en not_active Abandoned
- 2004-04-16 JP JP2006505187A patent/JP2006523651A/ja active Pending
- 2004-04-16 US US10/552,871 patent/US20060217395A1/en not_active Abandoned
- 2004-04-16 EP EP04739085A patent/EP1615641A1/fr not_active Withdrawn
- 2004-04-16 WO PCT/EP2004/004126 patent/WO2004091624A1/fr active Application Filing
- 2004-04-16 CA CA002522313A patent/CA2522313A1/fr not_active Abandoned
- 2004-04-16 CN CNA2004800171620A patent/CN1809355A/zh active Pending
- 2004-04-16 CA CA002522311A patent/CA2522311A1/fr not_active Abandoned
- 2004-04-16 RU RU2005135647/15A patent/RU2005135647A/ru not_active Application Discontinuation
- 2004-04-16 MX MXPA05011064A patent/MXPA05011064A/es unknown
- 2004-04-16 WO PCT/EP2004/004122 patent/WO2004091616A1/fr active Application Filing
- 2004-04-16 KR KR1020057019521A patent/KR20060003876A/ko not_active Application Discontinuation
- 2004-04-16 JP JP2006505188A patent/JP2006523652A/ja active Pending
- 2004-04-16 JP JP2006505185A patent/JP2006523649A/ja active Pending
- 2004-04-16 EP EP04739086A patent/EP1615642A1/fr not_active Withdrawn
- 2004-04-16 US US10/552,870 patent/US20060241143A1/en not_active Abandoned
- 2004-04-16 CN CNA2004800172252A patent/CN1809359A/zh active Pending
- 2004-04-16 WO PCT/EP2004/004124 patent/WO2004091617A1/fr active Application Filing
- 2004-04-16 BR BRPI0409377-1A patent/BRPI0409377A/pt not_active Application Discontinuation
- 2004-04-16 WO PCT/EP2004/004121 patent/WO2004091615A1/fr active Application Filing
- 2004-04-16 KR KR1020057019520A patent/KR20060003875A/ko not_active Application Discontinuation
- 2004-04-16 MX MXPA05011063A patent/MXPA05011063A/es unknown
- 2004-04-16 US US10/552,869 patent/US20060241124A1/en not_active Abandoned
- 2004-04-16 EP EP04727896A patent/EP1653956A1/fr not_active Withdrawn
- 2004-04-16 RU RU2005135649/15A patent/RU2005135649A/ru not_active Application Discontinuation
- 2004-04-16 EP EP04727895A patent/EP1613325A1/fr not_active Withdrawn
-
2005
- 2005-10-06 ZA ZA200508067A patent/ZA200508067B/en unknown
- 2005-10-06 ZA ZA200508068A patent/ZA200508068B/en unknown
- 2005-10-14 CO CO05105292A patent/CO5700753A2/es not_active Application Discontinuation
- 2005-10-19 MA MA28561A patent/MA27730A1/fr unknown
- 2005-10-19 MA MA28562A patent/MA27731A1/fr unknown
- 2005-11-14 NO NO20055367A patent/NO20055367L/no not_active Application Discontinuation
- 2005-11-14 NO NO20055368A patent/NO20055368L/no not_active Application Discontinuation
- 2005-11-15 IS IS8128A patent/IS8128A/is unknown
- 2005-11-15 IS IS8129A patent/IS8129A/is unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27730A1 (fr) | Combinaisons de paroxetine et de 4-(s)-(4-acetyl-piperazin-1-yl-)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-acide carboxylique[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxiete | |
JP2005532372A5 (fr) | ||
TNSN04104A1 (fr) | Formulations pharmaceutiques de derives de platine. | |
RS53591B1 (en) | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF INTERNAL HEARING DISORDERS | |
ATE269846T1 (de) | N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen | |
TNSN07063A1 (fr) | Utilisations therapeutiques d'inhibiteurs de rtp801 | |
NO20055531L (no) | Preparat for forbedret kognisjon og hukommelse | |
NZ594369A (en) | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
BRPI0414448A (pt) | composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e um agonista/antagonista de estrogênio | |
MXPA04001364A (es) | Uso de bibn4096 en combinacion con otros farmacos anti-migrana para el tratamiento de migrana, composicion y equipo. | |
MA27474A1 (fr) | Vaccin | |
SE9902935D0 (sv) | Pharmaceutical compositions | |
HUP0402092A2 (hu) | 2-[5-(4-Fluorfenil)-3-piridilmetilaminometil]-kromán vegyületek és fiziológiásan elfogadható sói alkalmazása gyógyszerkészítmények előállítására | |
DE60135390D1 (de) | Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration | |
MA28224A1 (fr) | Nitro-oxyderives de medicaments contre l'hypertension. | |
ATE431147T1 (de) | Mittel zur behandlung des integrationsdysfunktionssyndroms | |
DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
WO2002053099A3 (fr) | Methodes et compositions de traitement d'une parodontopathie | |
BR0312410A (pt) | Formulações farmacêuticas de liberação controlada | |
EP2452674A3 (fr) | Compositions et procédés pour augmenter les niveaux de plaquettes dans le sang chez les êtres humains | |
CA2368352A1 (fr) | Procede de traitement de la neuro degenerescence | |
BR0005318A (pt) | Utilização de inibidores de secreção da apo b/mtp e agentes antiobesidade | |
SE9902936D0 (sv) | Pharmaceutical compositions | |
KR970032865A (ko) | 허혈성 심질환으로 고생하는 환자의 경색크기를 감소하기 위한 방법 | |
WO2006088648A1 (fr) | Préparations et méthodes pour le traitement de la dyslipémie |